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Abstract
Background: Recently, we reported a novel oligoguanidine
transporter system, polyarginine (R7), which, when conjugated to
spectroscopic probes (e.g., fluorescein) and drugs (e.g., cyclosporin
A), results in highly water-soluble conjugates that rapidly enter
cells and tissues. We report herein the preparation of the first R7
peptide conjugates and a study of their cellular and organ uptake
and functional activity. The octapeptide iORACK was selected for
this study as it is known to exhibit selective O protein kinase C
isozyme agonist activity and to reduce ischemia-induced damage
in cardiomyocytes. However, iORACK is not cell-permeable.
Results : Here we show that an R7-iORACK conjugate readily
enters cardiomyocytes, significantly outperforming iORACK
conjugates of the transporters derived from HIV Tat and from
Antennapedia. Moreover, R7-iORACK conjugate reduced is-
chemic damage when delivered into intact hearts either prior to or
after the ischemic insult.
Conclusions: Our data suggest that R7 converts a peptide lead
into a potential therapeutic agent for the ischemic heart. ß 2001
Elsevier Science Ltd. All rights reserved.
Keywords: Cardiomyocyte; Molecular transporter; Polyarginine;
iORACK; R7 ; OPKC
1. Introduction
Many drugs, drug candidates, and probe molecules fail
because of cellular uptake problems. To circumvent these
problems, the physical properties of the agent must be
optimized to achieve acceptable levels of passive entry
into cells, a process often requiring the synthesis and eval-
uation of numerous analogues. An emerging and highly
e¡ective alternative strategy involves conjugation of the
agent to a molecular transporter allowing agents with a
wider range of physical properties to enter cells [1]. Pep-
tides derived from HIV Tat [2,3] and from Antennapedia
[4] have been used as transporters of otherwise di⁄cult to
deliver agents. More recently, we have shown that short
oligomers of arginine can be used to enable or enhance
uptake of agents into cells that do not enter or do so only
poorly in unconjugated form [5]. We have also shown that
these transporters enable uptake into skin [6]. Peptides
represent a signi¢cant and emerging class of therapeutic
candidates that often su¡er from cellular uptake problems
[7]. Here, we describe how a cell-impermeable peptide
(iRACK) that regulates protein^protein interactions in-
volving protein kinase C (PKC) can be delivered into cells
and intact heart with retention of biological activity.
PKC comprises a family of signal-transducing serine/
threonine kinases. Activation of PKC is associated with
translocation of each PKC isozyme to di¡erent subcellular
sites. This isozyme-speci¢c translocation is mediated, at
least in part, by interaction with isozyme-speci¢c anchor-
ing proteins termed RACKs (receptors for activated C-ki-
nase) [8,9]. Because binding of the activated PKC isozyme
to its respective RACK determines the function of each
isozyme, potentiation of binding to RACK should selec-
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tively increase the cellular activity of the corresponding
isozyme. Using rational design, we demonstrated that
short PKC-derived peptides that mimic RACKs (termed
pseudo-RACK, or iRACK) induce translocation of their
corresponding isozymes, resulting in isozyme-selective
translocation and activation of PKC [18^20]. However,
this peptide, corresponding to the pseudo-RACK sequence
of OPKC, or iORACK (HDAPIGYD, OPKC85ÿ92), is in-
capable of entering into cells [17]. As a ¢rst attempt at
cellular delivery, the peptide was conjugated to the deliv-
ery peptide, penetratin, derived from the Drosophila An-
tennapedia homeodomain protein (RQIKIWFQNRR-
MKWKK) [22]. The peptides were coupled to the carrier
through a reducible cysteine^cysteine disul¢de bond, to
enable release of iORACK (cargo) from the transporter
after uptake.
Using this delivery conjugate of iORACK, we previ-
ously investigated the role of OPKC in the process of is-
chemic preconditioning. Ischemic preconditioning is a nat-
ural biological phenomenon that protects cells from
ischemic injury, ¢rst described by Murry et al. in 1986
[25]. In their study, they found that hearts that were ‘pre-
conditioned’ with short bouts of ischemia were more re-
sistant to cell death and functional loss when subjected to
a subsequent prolonged ischemic episode. Since their ini-
tial discovery, ischemic preconditioning has been a central
focus of cardiovascular research. Although many advances
towards determining worthy drug targets to mimic a pre-
conditioning e¡ect have been made, very few good candi-
dates have been identi¢ed. PKC has been shown by many
groups to be involved in preconditioning. However, due to
side e¡ects of isozyme non-selective PKC inhibitors and
activators, PKC has not been a viable drug target. Upon
development of our isozyme-selective PKC activators and
inhibitor peptides conjugated to the Antennapedia delivery
system, we previously determined that OPKC activation
mediates cardioprotection from ischemic damage [16,22].
Treatment of the cells with conjugate (500 nM) prior to
and throughout the experiment resulted in a 70% reduc-
tion in damage of isolated adult cardiac myocytes during
simulated ischemia [19]. Moreover, delivery of iORACK
as a transgene product provided similar protection from
ischemic injury to the intact heart of transgenic mice [19].
Our results suggest that if su⁄cient quantities of iOR-
ACK could be delivered into the intact heart, it would
have potential as a therapeutic agent. We therefore set
out to identify an e¡ective transporter for the iORACK
peptide. We compared delivery via R7 or r7 [5] to Tat and
Antennapedia systems. Delivery was tested both in iso-
lated adult rat myocytes and in intact heart, using retro-
grade perfusion through the coronary arteries and measur-
ing the increased resistance to ischemic damage as an
indirect measure of intracellular delivery. We found that
delivery of iORACK conjugated to R7 is the most e¡ec-
tive system for reducing cardiac damage by ischemia.
These results suggest that the R7 could be more generally
used to deliver peptides for fundamental mechanistic stud-
ies as well as for therapeutic applications.
2. Results
2.1. Protection from ischemia in isolated cardiomyocytes
by iORACK delivered by R7 and Tat- and
Antennapedia-derived peptides
Using releasable disul¢de conjugates of transporter pep-
tides (as their corresponding tri£uoroacetate salts) and
iORACK, we determined the relative e⁄cacy of R7 deliv-
ery peptide against the Antennapedia- and Tat-derived
peptides (Ant-iOR and Tat-iOR, respectively; see Table
1 for peptides’ composition). In a previous study, the iOR-
ACK-C-SS-C-Antennapedia conjugate at a concentration
of 500 nM was applied to isolated cardiomyocytes for 10
min prior to simulated ischemia and remained throughout
the experiment [19]. These conditions resulted in optimal
protection yielding 16 þ 5% cell damage, which constitutes
a 70% protection as compared with cells subjected to is-
chemia in the absence of this peptide. The e¡ect of ische-
mia was assessed by increased membrane fragility as in-
dicated by an increase in trypan blue uptake. In previous
studies we demonstrated that this assay directly corre-
sponded to damage assessed by leakage of intracellular
enzymes in the medium, staining with propidium iodide,
and changes in cell shape [21]. To compare the relative
e¡ectiveness of the three delivery systems, we elected to
use the conjugates under sub-optimal conditions, applying
peptide conjugate at a lower concentration (100 nM) and
only during the 10-min incubation prior to the ischemic
event. Under these conditions, cell-permeable Antennape-
dia- and Tat-peptide conjugates of iORACK (Ant-iOR
and Tat-iOR) provided 30% and 25% protection
Table 1
Peptides used in this study
Control peptide conjugates
(Ant-iOR) (iORACK-C-SS-C-Antennapedia)
HO2C-DYGIPADHC-SS-CRQIKIWFQNRRMKWKK-CONH2
(Tat-iOR) (iORACK-C-SS-C-HIV-Tat)
HO2C-DYGIPADHC-SS-CRKKRRQRRR-CONH2
(K7-iOR) (iORACK-C-SS-C-Lys7)
HO2C-DYGIPADHC-SS-CK7-CONH2
(NR 1-R7) (iORACK-Arg7)
NH2-R7-DYGIPADHC-CO2H
(NR 2-R7) (iORACK-aca-Arg7)
NH2-R7-aca-DYGIPADHC-CO2H
(R7 alone) (Arg7)
(R7-Scr-iOR) (scrambled iORACK-C-SS-C-Arg7)
HO2C-IGADHYDPC-SS-CR7-CONH2
Delivery conjugates
(R7-iOR) (iORACK-C-SS-C-Arg7)
HO2C-DYGIPADHC-SS-CR7-CONH2
(r7-iOR) (iORACK-C-SS-C-D-Arg7)
HO2C-DYGIPADHC-SS-Cr7-CONH2
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(29 þ 4% and 31 þ 7%, respectively, vs. 39 þ 3% cell dam-
age in the absence of any peptide, P6 0.05; Fig. 1). The
R7 conjugate of iORACK (R7-iOR) caused a 70% protec-
tion (there was 16 þ 6% cell damage, P6 0.05; Fig. 1),
representing a 2.8-fold increase in protection from ische-
mia relative to the Antennapedia conjugate and a 2.3-fold
increase relative to the Tat conjugate (Fig. 1). Control
studies indicated that the R7 peptide alone (R7 alone) or
the R7 peptide conjugated to a scrambled iORACK pep-
tide (R7-Scr-iOR) had virtually no e¡ect (the percentage
of ischemia-induced damaged cells was 45 þ 4% and
44 þ 3% respectively, vs. 39 þ 3% in the absence of any
peptide, P = not signi¢cant; ns). Therefore, the protection
conferred by only 100 nM R7 conjugate (R7) when prein-
cubated with the cells for 15 min prior to prolonged ische-
mia was similar to the protection provided by the Anten-
napedia delivery system under optimal conditions (500 nM
peptide added 15 min prior to the ischemia as well as
during the ischemia) in the previous study described above
(16 þ 5% vs. 16 þ 6% cell damage, respectively; Fig. 1 and
[19]). The present study demonstrates that the R7 trans-
porter system enables the e⁄cient delivery of a therapeuti-
cally bene¢cial peptide that by itself could not enter cells.
Furthermore, R7 was a superior vehicle for peptide deliv-
ery as compared with the currently available Tat and An-
tennapedia delivery systems.
2.2. iORACK cannot be delivered by any cationic peptide
To determine if the cationic nature of the R7 peptide
conjugate was responsible for its e⁄cient delivery, a hep-
tamer of L-lysine was used. The releasable polylysine di-
sul¢de conjugate of iORACK (K7-iOR) provided no pro-
tection from ischemia (53 þ 6% vs. 39 þ 7% cell damage,
P = ns; Fig. 1) and, in fact, appeared to be deleterious.
The failure of K7-iOR to elicit the desired response indi-
cates, in accord with previous studies [5], that transport is
a speci¢c function of the guanidine head groups present in
the oligo-arginine.
2.3. Delivery of iORACK by the D-isomer of R7 (r7)
We have previously shown that the D-isomer of the oli-
go-arginine sequence, denoted r7, can also be transported
across cellular membranes [5]. The activity of the D-isomer
is important for biological applications because it provides
greater resistance to protease degradation of the peptides.
Therefore, the protection rendered by iORACK peptide
conjugated to r7 was determined. The r7iORACK conju-
gate (r7-iOR) provided a 60% reduction in ischemia-
induced cell damage (20 þ 5% vs. 39 þ 7%, P6 0.05;
Fig. 1). These data show that the D-isomer of the transport
peptide is almost equally e¡ective as the L-isomer at facil-
itating peptide delivery.
2.4. Delivery of iORACK by non-releasable constructs
of R7
To determine the necessity of release of the iORACK
peptide, two non-releasable (NR) constructs were synthe-
sized and evaluated. NR 1-R7 and NR 2-R7 are direct
conjugates of the delivery peptide to iORACK, the key
di¡erence between the two being an O-aminocaproic acid
spacer group present in NR 2-R7. There was no signi¢cant
reduction in ischemia-induced cell damage when either NR
1-R7 or NR 2-R7 were pre-incubated with the myocytes
(39 þ 3% and 43 þ 1% vs. 39 þ 7%, P = ns, respectively;
Fig. 1). These results indicate that, under the conditions
employed here (100 nM peptide applied 10 min prior to
the prolonged ischemia only), release of the parent peptide
is essential for its biological activity
2.5. Delivery of R7-C-SS-C-iORACK to whole hearts,
prior to ischemic insult
The suitability of the iORACK as a cardioprotective
agent for clinical use and the e¡ectiveness of the R7 trans-
port system were next evaluated in a whole organ model.
Using retrograde perfusion via the coronary arteries, iOR-
ACK-C-SS-C-R7 (R7-iOR) was administered into rat
heart over a period of 20 min prior to no-£ow global
ischemia (45 min). After ischemia, hearts were reperfused
for 30 min and fractions were collected at 150-s intervals
Fig. 1. Comparison of e⁄cacy of peptide delivery systems. Carrier pep-
tides are compared for their ability to confer protection of isolated car-
diomyocytes from ischemic damage by delivery of iORACK. (A) Sche-
matic of treatment protocol. (B) Protection from ischemic damage.
Myocytes were treated with 100 nM of the following carrier peptide-
iORACK conjugates prior to ischemia: iORACK-C-SS-C-Antennapedia
(Ant-iOR), iORACK-C-SS-C-Tat (Tat-iOR), iORACK-C-SS-C-Arg7
(R7-iOR), iORACK-C-SS-C-Arg7 (r7-iOR), iORACK-C-SS-C-Lys7
(K7-iOR), iORACK-Arg7 (NR 1-R7), iORACK-aca-Arg7 (NR 2-R7),
Arg7 (carrier peptide alone, R7-alone), scrambled iORACK-C-SS-C-
Arg7 (R7-Scr-iOR). Cells were compared to no treatment (3) and no is-
chemia (normoxia) as controls. Percent of cell damage (left axis) is
calculated as increase of percent cells exhibiting decreased membrane in-
tegrity. Data are also presented as percent reduction in damage (right
axis) as compared to non-treated cells (second bar). Data are mean þ
S.E.M. of three experiments.
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during reperfusion (Fig. 2A). Cardiac damage was as-
sessed by measuring release of the intracellular cardiac-
speci¢c enzyme creatine phosphokinase (CK) during the
reperfusion period (Fig. 2B). Typically, ischemic events
result in the release of large quantities of CK compared
to a heart maintained under normoxic conditions. As seen
in Fig. 2C, iORACK-C-SS-C-R7 (R7-iOR) caused a 78%
reduction in CK release measured during 30 min of reper-
fusion (1.5 þ 0.7 vs. 7.2 þ 0.6, P6 0.05). Under the same
conditions, iORACK-C-SS-C-Tat caused a 50% reduction
in CK release (3.6 þ 0.1 vs. 7.2 þ 0.6, P6 0.05). As with the
isolated myocytes, there was no protection at any of the
times tested with R7 alone, scrambled iORACK-C-SS-C-
R7 or iORACK-C-SS-C-K7 (9.9 þ 1.5, 7.5 þ 1.8, and
8.9 þ 1.0, P = ns, respectively; Fig. 2C). These data dem-
onstrate that delivery of the iORACK peptide to whole
organs prior to an ischemic event signi¢cantly reduces
ischemia-induced cell damage. Furthermore, they show
that the R7 delivery peptide surpasses Tat peptide-medi-
ated delivery not only in an isolated cell system, but also
in whole organ delivery.
2.6. Delivery of R7-C-SS-C-iORACK to whole hearts after
an ischemic insult
Patients arriving after a cardiac ischemic event is a clin-
ically common situation. Therefore, we determined
whether R7-iORACK confers protection from ischemia
when applied after 45 min of global ischemia. Hearts
were treated with R7-iORACK for the ¢rst 20 min of
the 60-min reperfusion period and CK release was mea-
sured to assess cardiac damage over time (Fig. 3A). Hearts
treated with R7-iORACK had less damage at all time
points within 15 min after peptide delivery (Fig. 3B).
There was a 48% reduction in CK release compared to
untreated hearts (12 þ 2 vs. 21 þ 2, P6 0.05; Fig. 3C).
Taken together, these data indicate that treatment of
whole hearts with iORACK conjugated to R7 confers pro-
Fig. 2. Delivery of iORACK to whole hearts prior to an ischemic insult
confers protection from ischemic damage. (A) Schematic of treatment
protocol. Whole hearts were perfused with peptides 20 min prior to 45
min global ischemia. Hearts were then reperfused for 30 min. Ischemia-
induced cell damage was determined by measuring the creatine phospho-
kinase enzyme present in the perfusate during reperfusion. Creatine
phosphokinase is a cytosolic enzyme in cardiac myocytes and its pres-
ence in the perfusate is proportional to the number of cardiomyocytes
damaged by the ischemic period. (B,C) Protection from ischemic dam-
age. Whole hearts were treated with 500 nM of the following carrier
peptide iORACK conjugates prior to ischemia: iORACK-C-SS-C-Tat
(Tat-iOR), iORACK-C-SS-C-Arg7 (R7-iOR), iORACK-C-SS-C-Lys7
(K7-iOR), Arg7 (R7 alone), scrambled iORACK-C-SS-C-Arg7 (R7-Scr-
iOR). Treated hearts were compared to no treatment and no ischemia
(normoxia) as controls. Data are represented as cell damage as a func-
tion of time during reperfusion (B) and total cell damage during the re-
perfusion period (C) (n = 4, *P6 0.05, ns = not signi¢cant).
Fig. 3. Delivery of iORACK to whole hearts after an ischemic insult
confers protection from ischemic damage. (A) Schematic of treatment
protocol. Whole hearts undergo 45 min of global ischemia. Hearts are
then perfused with or without peptide for 20 min followed by 40 min
perfusion without peptide. Ischemia-induced cell damage determined by
creatine phosphokinase activity in perfusate collected during reperfusion
(as in Fig. 2). (B,C) Protection from ischemic damage. Whole hearts are
treated with 500 nM of iORACK-C-SS-C-Arg7 (R7-iOR) after an ische-
mic insult and compared to untreated hearts as a control. Data are rep-
resented as cell damage as a function of time during reperfusion (B)
and total cell damage during the reperfusion period (C) (n = 4;
*P6 0.05, ns = not signi¢cant).
CHBIOL 140 12-12-01 Cyaan Magenta Geel Zwart
1126 Chemistry & Biology 8/12 (2001) 1123^1129
tection when applied both prior to and after an ischemic
insult.
3. Discussion
In this study, we successfully transported a cell-imper-
meable octapeptide, iORACK, into isolated cardiac myo-
cytes and into intact heart using the oligo-arginine (R7)
conjugated to a biologically active peptide (iORACK)
through a simple Cys^Cys disul¢de bond. iORACK deliv-
ery by R7 (iORACK-C-SS-C-R7) was demonstrated by
the increased resistance of isolated cardiomyocytes and
intact heart to damage induced by prolonged ischemia.
Although it is possible that cardioprotection is promoted
by a release of cardioprotective agents from a few cells
that obtained iORACK-C-SS-C-R7, our data are more
consistent with the possibility that the 70% protection of
the intact heart from ischemia indicates that at least 70%
of the cardiac muscle received the therapeutic peptide. In
that case, our data suggest that iORACK-C-SS-C-R7
crossed the endothelial cells of the blood vessels and sev-
eral muscle cells and ¢broblasts to exert its full e¡ect,
demonstrating that R7 can convert peptides that act intra-
cellularly into viable drug candidates.
Of the four delivery peptides tested (Antennapedia-de-
rived peptide, Tat-derived peptide and the R7 and r7), the
R7 and r7 conjugates of iORACK (100 nM) conferred the
highest levels of protection from ischemia-induced damage
in isolated cardiac myocytes (70 and 60% reduction; Fig.
1). The Tat-derived conjugate (Tat) was equal to the An-
tennapedia conjugate in delivery of the iORACK activity,
but was two-fold less e¡ective than the R7. The product of
the non-reducible cross-linking of iORACK to R7 (NR
1-R7 and NR 2-R7) was biologically inactive under the
same assay conditions, indicating that the delivery system,
in this case, must release iORACK in order for the latter
to function biologically. iORACK conjugated to oligo-ly-
sine (K7-iOR) was also inactive demonstrating that the
guanidine head groups present in these transport peptides
are required for transport activity. The apparent deleteri-
ous e¡ect of the polylysine conjugate is most likely an
artifact of the transport peptide’s inherent toxicity.
Importantly, cardioprotection was conferred to whole
hearts treated with iORACK conjugated to R7 prior to
ischemia (Fig. 2). These data suggest the potential use of
iORACK-R7 as a therapeutic agent in situations where
the timing of an ischemic episode can be predicted. In
many procedures such as open heart surgery, bypass sur-
gery, and heart transplantation, this is indeed the case. Of
even greater clinical importance, we found that delivery of
iORACK using R7 rendered the heart more resistant to
ischemic and reperfusion damage when the peptide was
applied after the ischemia and during the reperfusion stage
(Fig. 3). These ¢ndings suggest a potential use for these
peptides in even more common clinical settings, such as
acute cardiac ischemia. Acute myocardial ischemia is re-
sponsible for up to 500 000 deaths per year in the USA
alone and nearly 14 million worldwide. Because more than
half of these deaths occur in the hospital, an improved
therapeutic intervention such as the one described here
could save many lives.
Studies in the last few years identi¢ed many peptides
that interfere with protein^protein interaction inside cells
(e.g., those that a¡ect L-adrenergic G-protein signaling
[10], Lyn function [11], protein kinase A signaling [12^
15], and PKC signaling [23]). Traditionally, these peptides
are not considered drug candidates; more often, they are
used as leads for high throughput screening of non-peptide
compounds or to provide a proof-of-principle for gene
delivery approaches. Here, we show that R7 can transport
peptides through the blood vessels into an intact organ,
demonstrating that such peptide conjugates could them-
selves be used as drugs. Moreover, such delivery of a pep-
tide results in transient biological activity and therefore,
unlike gene delivery, is completely reversible. Although the
stability of the peptides in the blood could be a concern in
general, the demonstrated e¡ectiveness of the D-isomer (r7)
provides an e¡ective solution to this problem. In addition,
the ability to deliver the peptide nearby the target organ,
such as the case for intra-coronary delivery, is likely to
reduce the e¡ects on other organs. Finally, peptide drug
instability in the blood could be overcome, if su⁄cient
delivery of the peptide conjugate occurs during its ¢rst
pass through the organ. In fact, there might be an advan-
tage if the peptides are not very stable in the blood, as this
will reduce their e¡ects on organs other than the heart. In
summary, through the use of R7, iORACK is converted
into a potential therapeutic agent for the treatment of
acute ischemic heart disease both before and after the is-
chemic event. If con¢rmed in humans, iORACK delivered
by R7 would provide an e¡ective therapeutic agent for the
treatment of ischemic heart disease.
4. Signi¢cance
The ability to enable or enhance the uptake of agents
into cells or tissue can have major implications in the
development of new drugs or in the resurrection of pre-
viously non-viable drug candidates. Peptides in particular
are often limited as potential drug candidates due to in-
herently poor bioavailability and rapid degradation. The
work described herein demonstrates that by ligation to an
oligoguanidine transporter moiety, a peptide agonist of
OPKC, unable by itself to penetrate cells, can be delivered
across multiple layers of tissue and into cells and subse-
quently released to act at its intracellular target. This up-
take phenomenon is a speci¢c function of the guanidine
head groups present in the transporter peptide and is not
simply due to its cationic nature. Cleavage of a disul¢de
bond between the peptide transporter and peptide cargo
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allows for intracellular release of the free peptide cargo
and in vivo activity. This overall approach provides a
general method for the in vivo delivery of bioactive agents
including notably peptides that alone have limited poten-
tial as therapeutic agents.
In this speci¢c study, transporter-enabled delivery of a
peptide cargo through the coronary arteries demonstrates
the opportunity provided by this cellular delivery method
to introduce therapeutic agents designed to protect the
myocardium from known ischemic episodes. Prophylactic
treatment for patients at risk from ischemic heart disease,
therapies for coronary artery bypass surgery and trans-
plant preservation can now be realized given the capabil-
ities of this delivery technology and the biological activity
of these peptides. With the advent of this delivery technol-
ogy, many new therapeutic agents become available.
5. Materials and methods
5.1. Peptides
Peptides were synthesized using a PE Biosystems model 433A
Automated Peptide Synthesizer. The acid- or amide-linked resins,
appropriately protected amino acids (arginine was protected as its
2,2,4,6,7-pentamethyldihydro-benzofuran-5-sulfonyl (Pbf) deriva-
tive, tryptophan as its N-t-butoxycarbonyl (t-BOC) derivative,
and cysteine as its S-trityl (Trt) derivative) and synthesizer re-
agents were purchased from Bachem or Novabiochem. Peptides
were prepared using the standard FastMoc protocol on either a
0.1 mmol or 0.25 mmol scale.
Non-cysteine-containing peptides were cleaved from resin sup-
ports using 95% tri£uoroacetic acid (TFA):5% triisopropylsilane
for 4 h. Peptides containing cysteine were cleaved using 85%
TFA, 5% thioanisole, 2.5% triisopropylsilane, 2.5% phenol,
2.5% water, and 2.5% ethanedithiol for 4 h. In all cases, the ¢nal
products were obtained in analytical purity (ESI-TOF MS and
analytical HPLC) using a Varian Model HPLC system ¢tted with
a Varian C18-packed reverse phase column.
5.2. Peptide conjugates
Disul¢de conjugates were prepared by the following general
procedure [24]: 2,2P-dithiobis(5-nitropyridine) (5 eq) was dis-
solved in a minimal amount of 3:1 acetic acid:water over a peri-
od of 30 min at room temperature. Once the reagent had mostly
dissolved, HS-C-R7-CONH2 (1 eq) was added as a solution in
1 ml of 3:1 acetic acid:water. The orange solution slowly devel-
oped a bright yellow and was permitted to stir overnight at room
temperature. The reaction was quenched by removal of the sol-
vent in vacuo. The residue was reconstituted in an equal volume
mixture of water and ethyl acetate. The layers were separated and
the aqueous phase was extracted with ethyl acetate until no
yellow color remained. The aqueous layer was concentrated in
vacuo to provide the activated disul¢de, N-Pys-SS-CR7-CONH2,
which was used directly without further puri¢cation.
The N-Pys-SS-CR7-CONH2 in 2 ml of argon-degassed water
was treated with HS-CHDAPIGYD-CO2H (1 eq). Upon addition
of the second peptide, a bright yellow color was immediately
apparent. After stirring for 16 h at room temperature, the reac-
tion was diluted with ethyl acetate. The phases were separated
and the aqueous layer was extracted with ethyl acetate until no
yellow color remained. The water was removed via lyophilization
and the residue puri¢ed by RP-HPLC (C-18 column using a
5^50% acetonitrile :water gradient over 30 min) to furnish the
desired peptide in typically s 60% overall yield. The identity
and purity of the individual conjugates was established using
analytical RP-HPLC in conjunction with ESI-TOF MS. All con-
jugates employed in this study were used as their corresponding
tri£uoroacetate salts bearing a full complement of counterions.
5.3. Ischemia-reperfusion of isolated adult rat heart and creatine
kinase assay
Ischemia of isolated adult cardiac myocytes and peptide treat-
ments were carried out as previously described [19]. For whole
organ ischemia, hearts from adult male Sprague^Dawley rats
(250^300 g) were isolated and perfused on a Langendor¡ appa-
ratus. Perfusion was performed at constant pressure of 85 mm Hg
at 37‡C using Krebs^Henseleit bu¡er (118 mM NaCl, 4.7 mM
KCl, 25 mM NaHCO3, 1.2 mM KH2PO4, 1.2 mM MgSO4, 3 mM
CaCl2 and 5 mM glucose (pH 7.4)). The perfusate was then
oxygenated by continuous bubbling of 95% O2/5% CO2. After
the initial l0-min equilibration period, hearts were perfused for
20 min with 500 nM of the indicated peptide conjugate in the
bu¡er solution, followed by 45 min of no-£ow simulated ische-
mia. Immediately following ischemia the hearts were subjected to
30 min of reperfusion. Samples of coronary venous out£ow were
collected every 2.5 min during the reperfusion period (total of 12
fractions). Creatine phosphokinase (CK) release was assayed us-
ing a calorimetric determination kit (Sigma) to measure the extent
of cardiac injury. Where indicated, iORACK peptide conjugate
was perfused into the heart only after the 45 min no-£ow ische-
mia, for the ¢rst 20 min of reperfusion. CK release was moni-
tored during this period and an additional 40 min of reperfusion,
and assayed as above.
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